[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-back-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-back-pain":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,45,66,93,121,164,193,220,253,275,295,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100635992","monopolar-basivertebral-nerve-ablation-for-axial-low-back-pain-100635992",false,"NCT07559890","Monopolar Basivertebral Nerve Ablation for Axial Low Back Pain","Monopolar Basivertebral Nerve Ablation for Axial Low Back Pain - Single-Arm Proof-of-Concept Study","Inclusion Criteria:\n\n* Axial low back pain (with or without lateral component).\n* Presence of Modic type I or II changes at ≥ 1 level.\n* Age over 18 years.\n* Duration of pain ≥ 6 months.\n* Completion of full conservative management for ≥ 3 months.\n\nExclusion Criteria:\n\n* Coagulation disorders.\n* Platelet abnormalities.\n* Lack of informed consent.\n* Generalized solid tumor.\n* Hematopoietic malignancy.\n* Radicular pain.\n* Alternative primary pain generators other than axial low back pain.\n* Previous spinal surgery.\n* Targeted level located above L3\u002FL4\n* Osteoporosis","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","Determination of efficacy and safety of Monopolar Basivertebral Nerve Ablation for Axial Low Back Pain treatment, including the method optimization.",[26,27],"Chronic Back Pain","Basivertebral Nerve Ablation",[29,30,31],"chronic back pain","basivertebral nerve ablation","radiofrequency","RECRUITING","2026-06-04",{"date":35,"type":36},"2026-06-05","ACTUAL",{"date":38,"type":36},"2026-05-04",{"date":40,"type":20},"2029-05",{"name":42,"class":43},"EPC Education s.r.o.","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100383281","the-effect-of-yoga-practice-on-chronic-back-pain-100383281","NCT04270617","The Effect of Yoga Practice on Chronic Back Pain","A Prospective, Randomized-controlled Study to Evaluate the Effect of a Standardized Yoga Practice on Chronic Back Pain","Inclusion Criteria:\n\n* Willingness to and ability to participate in study procedures\n* Chronic back pain (pain above the gluteal cleft of at least 3 months duration)\n\nExclusion Criteria:\n\n* Indication for surgery (i.e., fracture, infection, scoliosis, spondylolisthesis)\n* Cardiac, pulmonary or other medical comorbidities that preclude participation in yoga practice",{"count":53,"type":20},200,[23],"Chronic low back pain is notoriously difficult to treat and is a primary contributor to lost work days and excessive health expenditures, and whose treatment has, in part, contributed to the opioid crisis. Surgery is only an option in a minority of these patients, usually confined to those with structural instability. Yoga is an ancient modality whose benefits are currently being studied.",[26],"2026-06-03",{"date":33,"type":36},{"date":60,"type":36},"2019-12-01",{"date":62,"type":20},"2028-01",{"name":64,"class":43},"NYU Langone Health",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":65},"100633646","percutaneous-auricular-vagus-nerve-stimulation-with-conventional-rehabilitation-training-in-chronic-back-pain-patients-100633646","NCT07529392","Percutaneous Auricular Vagus Nerve Stimulation With Conventional Rehabilitation Training in Chronic Back Pain Patients","Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Combined With Conventional Rehabilitation Training to Improve Functional Outcome in Chronic Back Pain Patients (CURA): A Randomized Controlled Pilot Study","CURA","Inclusion Criteria:\n\n* Male or female aged ≥30 and ≤65 years\n* Indication: chronic myofascial\u002Fmusculoskeletal back pain\n* normal function of spinal nerves\n* Intractable pain for more than 6 months\n* Patient on oral pharmacotherapy ≤ WHO II with no adequate response or intolerant\n* Severity according to \"Leistungskategorie 2\" of BVAEB classification, which means Barthel Index 35-80, 6-minute walk test 300-480 m OR ergometry 50-80%\u002F0.75-1.25, ICF-Core-Sets grade 3\n* Average pain over the last 4 weeks according to painDETECT ≥ 4 and ≤ 9 at baseline\n* ODI 20-80 at baseline\n* Patient understands the therapy and procedures, agrees to its provisions, and gives written informed consent prior to any procedures\n\nExclusion Criteria:\n\n* Organic back pain (trauma, fracture, tumor, infection, severe degenerative spine, documented high-grade spinal stenosis, rheumatologic conditions)\n* Indication for back surgery\n* Radicular pain\n* Back surgery within the last 6 months\n* New analgesics 2 weeks before baseline (paracetamol, NSAIDs, Metamizol, etc.)\n* Opioid analgesic therapy \\> WHO II\n* Underwent other physical therapy modalities for back pain, also TENS, 2 weeks before baseline\n* History of vagus nerve stimulation or electrical auricular stimulation\n* History of vasovagal syncope\n* High BMI \\> 35 kg\u002Fm² (Obesity Class 2 or higher)\n* Hemophilia or strong anti-coagulation medication\n* Autonomic disorders\n* Advanced stage or poorly controlled diabetes mellitus type I or II\n* Poorly controlled high blood pressure\n* Major psychiatric comorbidity (at the discretion of the PI)\n* Other serious clinically relevant co-morbidity\n* History of arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies\n* Infection, eczema, or psoriasis at application site (ear and neck)\n* Numbed and desensitized skin at the application site (ear and neck)\n* Chronic drug or alcohol abuse within the last 6 months\n* Pregnant or nursing female patients\n* Active implantable device\n* Open pension request\n* Currently participating in another clinical trial or participated over the last 3 months\n* Relevant change in concomitant treatment or medication during the study","30 Years","65 Years",{"count":77,"type":20},48,[23],"The therapeutic action of aVNS in pain treatment is based on the masking of pain by the electrical stimulation pulses, the activation of inhibiting pain control systems, and the release of neurotransmitters, such as endorphins. Pairing VNS stimulation with exercise and physiotherapy has yielded beneficial results in stroke patients as well as in smaller studies with back pain patients, already in short periods of time (2-4 weeks).\n\nThe current study is intended to evaluate the performance of percutaneous auricular Vagus Nerve Stimulation (pVNS) in combination with Standard-of-Care (SoC) in a 3-week in-patient rehabilitation setting, in patients with chronic musculoskeletal\u002Fmyofascial back pain. This will be a prospective, open, randomized, controlled pilot study to evaluate pVNS using the VIVO® wearable medical device for personalized pain treatment, in terms of feasibility, efficacy, and safety in combination with rehabilitation training. Patients will be randomized into one of the following treatment groups:\n\n* Group A: VIVO® (pVNS) + SoC (treatment group)\n* Group B: SoC (control\u002Fcomparator group) Patients will remain on treatment for 3 weeks. This is comparable to other studies performed earlier, which showed safe and effective use of pVNS in chronic pain patients. The additional follow-up period of 3 weeks (optional 3 months and 6 months) allows to evaluate sustainable effects of treatment and late time effects, as previously shown in other studies.\n\nPatients in the treatment group (VIVO® + SoC) will receive personalized aVNS therapy in combination with SoC. Personalization of VIVO® treatment is performed based on the individual perception level of the stimulation at the ear with regards to the stimulation amplitude (in Group A). Amplitude is adjusted (range 0-5 V) to reach a distinct but comfortable tingling sensation to reach activation of Aβ-fibers of the auricular vagus nerve but not Aδ-fibers producing a sensation of pain. Not only the Investigator is able to adjust the amplitude at the trial visit (via VIVO® Pen) but also the patient is able to adjust the amplitude according to his\u002Fher perception.\n\nPatients will be randomized in this pilot study to receive either aVNS with the VIVO® system in addition to SoC vs. SoC alone as comparator group. Estimates of performance endpoints will thus be contrasted between aVNS and an established treatment option in this indication and controlled for regression to the mean and other forms of sampling bias.\n\nAll concomitant medication and therapies will be thoroughly documented and taken into account in the final analysis.",[26],[82,83],"Percutaneous Auricular Vagus Nerve Stimulation","Rehabilitation","2026-04-21",{"date":86,"type":36},"2026-04-24",{"date":88,"type":36},"2025-11-27",{"date":90,"type":20},"2027-03-15",{"name":92,"class":43},"Medical University of Vienna",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":65},"100595495","virtual-reality-treatment-for-adults-with-chronic-back-pain-vrnt-100595495","NCT07033195","Virtual Reality Treatment for Adults With Chronic Back Pain (VRNT)","Efficacy of a Virtual Reality Neuroscience-based Therapy (VRNT) for Chronic Low Back Pain","Inclusion Criteria:\n\n* Men and women aged 18 to 85.\n* Self-reported diagnosis of chronic low back pain without radicular symptoms.\n* Chronic low back pain duration of 6 months or more, and pain at least half the days in the last 6 months.\n* Lower back pain as primary chronic pain complaint (greater than pain in other bodily regions).\n* Average pain intensity of 4 or more out of 10 for the past week (from BPI-SF).\n* English fluency (8th grade level).\n* Willing to comply with study procedures\u002Frestrictions.\n* Access to Wi-Fi.\n* Implicit de facto internet and computer literacy.\n\nExclusion Criteria:\n\n* Applicants, who are pregnant, planning pregnancy, or breastfeeding\n* Back pain associated with compensation \u002F litigation within 1 year.\n* Leg pain greater than back pain (suggests neuropathic pain; may be less responsive to psychological therapy).\n* Chronic pain other than chronic back pain.\n* Diagnoses of schizophrenia, multiple personality dissociative identity disorder.\n* History of major depressive disorder not controlled with medication or other conditions that produce significant cognitive or emotional disability.\n* History of substance abuse.\n* Inability to undergo MRI (determined at screening; see XVI: Risks to Participants).\n* Any clinically significant unstable medical abnormality or acute or chronic disease of cardiovascular, gastrointestinal, respiratory (e.g., chronic obstructive pulmonary disease), hepatic, or renal systems; including: history of cardiovascular disease or issues (e.g., recent heart attack), stroke; brain surgery, or brain tumor; Diabetes; cancer (last 12 months); diagnosis of a specific inflammatory disorder: rheumatoid arthritis, polymyalgia rheumatica, scleroderma, Lupus; polymyositis; or Cauda Equina syndrome.\n* History of seizure disorder, epilepsy, convulsions, or increased intracranial pressure anytime except pediatric febrile seizures.\n* History of vertigo, dizziness, susceptibility to motion sickness\n* History of head injury within 6 months,\n* Unexplained, unintended weight loss of 'â• 20 lbs in past year. Self-reported history of (digital) eye strain or computer vision syndrome. Unable or unwilling to meet study attendance requirements. MRI contraindications as determined by MRI safety screen (e.g., pregnancy, metal in body, claustrophobia, using the standard screen conducted by the MRI imaging facility).","85 Years",{"count":53,"type":20},[23],"Participants with chronic back pain will complete an online Qualtrics eligibility survey. After signing a consent form, eligible participants enter a two-week baseline period (\"Baseline Period\"), during which they complete two assessments of the Primary and Secondary Outcome Measures and Potential Mediators. After the baseline period, participants are randomized into a Virtual Reality group: VR Distraction-based Therapy or VR Skills-based Therapy, with a 1:1 allocation ratio of participants to each treatment. Both groups receive education on pain neuroscience and complete training on the use of the VR hardware and software. Next, both groups complete an intervention for 8 weeks (\"Treatment Period\"), after which they return the VR equipment. Several surveys are administered online during the Treatment Period. After the Treatment Period, both groups complete three post-treatment surveys at weeks 8, 20, and 32.",[105,26,106],"Chronic Pain","Chronic Lower Back Pain (CLBP)",[108,109,29,110],"chronic pain relief","back pain","chronic lower back pain","2026-04-01",{"date":113,"type":36},"2026-04-02",{"date":115,"type":36},"2025-06-01",{"date":117,"type":20},"2027-05-20",{"name":119,"class":120},"CognifiSense Inc.","INDUSTRY",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":137,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100631700","active-coping-interdisciplinary-program-for-chronic-pain-physiotherapy-unit-spain-100631700","NCT07504094","Active Coping: Interdisciplinary Program for Chronic Pain, Physiotherapy Unit (Spain)","Interdisciplinary Active Coping Program for Chronic Pain in the Physiotherapy Unit in Primary Care - Teruel Health Sector (Aragón, Spain)","Inclusion Criteria:\n\n* Adult (18 years or older)\n* Diagnosis of non-oncological chronic back pain\n* Referred from Primary Care to the Physiotherapy Unit of Teruel Ensanche . (UFAP) from one of the following basic health zones: Teruel Centro, Teruel Ensanche, Albarracín, Alfambra, Cella, or Villel\n* Able to provide voluntary written informed consent\n\nExclusion Criteria:\n\n* Oncological pain\n* Cognitive impairment that prevents following the program\n* Spinal surgery in the last year\n* Internal electrostimulator device (e.g. pacemaker, spinal cord stimulator)",{"count":129,"type":20},20,[23],"The goal of this observational intervention study is to evaluate the impact of a multidisciplinary active coping program for chronic back pain in adults referred from Primary Care to the Physiotherapy Unit of Teruel Ensanche. The main questions it aims to answer are:\n\n* Does the program improve physical function, measured through gait speed, balance, and chair stand tests?\n* Does it reduce pain-related psychological factors such as kinesiophobia, catastrophizing, anxiety, and depression?\n* Does it improve quality of life and sleep quality, and reduce analgesic medication use?\n\nParticipants will attend group sessions on pain neuroscience education, followed by sessions on healthy habits, nutrition and sleep hygiene and group psychological intervention focused on emotional wellbeing tools, and will complete therapeutic exercise sessions over the course of the program. They will also complete validated questionnaires and physical assessments at three timepoints: at baseline, at the end of the program, and at a 6-month follow-up.",[26,105,133,134,135,136],"Back Pain","Low Back Pain, Chronic","Musculoskeletal Pain","Kinesiophobia",[138,139,140,141,142,26,143,144,145,146,147,148,149,150,151,152,153],"Pain Neuroscience Education","Therapeutic Exercise","Multidisciplinary Intervention","Active Coping","Psychological Intervention","Chronic Musculoskeletal Pain","Central Sensitization","Pain Catastrophizing","Primary Care","Physiotherapy","Primary Care Physiotherapy Unit","Quality of Life","Physical Function","Sleep Quality","Anxiety","Depression","NOT_YET_RECRUITING","2026-03-26",{"date":157,"type":36},"2026-03-31",{"date":111,"type":20},{"date":160,"type":20},"2028-02",{"name":162,"class":43},"Universidad de Zaragoza",2,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":65},"100608196","effect-of-sedation-after-ultrasound-guided-spinal-anesthesia-on-back-pain-100608196","NCT07198412","Effect of Sedation After Ultrasound-Guided Spinal Anesthesia on Back Pain","Impact of Ultrasound-Guided Spinal Anesthesia and Pre-Procedure Sedation on Postoperative Acute and Chronic Back Pain in Non-Obstetric Surgery.","Inclusion Criteria\n\nAdults aged 18-65 years ASA physical status I-II Body Mass Index (BMI) ≤ 35 kg\u002Fm² Scheduled for elective non-obstetric lower abdominal or lower limb surgery under spinal anesthesia Able to provide written informed consent\n\nExclusion Criteria\n\nContraindications to spinal anesthesia (e.g., coagulopathy, local infection at puncture site) Pre-existing chronic low back pain Chronic opioid use Known allergy or contraindication to study medications (bupivacaine, lidocaine, midazolam) Psychiatric or neurological disorders affecting pain perception or reporting Severe spinal deformities or history of previous spinal surgery Inability to comply with follow-up assessments",{"count":172,"type":20},180,[23],"This study will evaluate whether giving sedation before spinal anesthesia, when performed with ultrasound guidance, reduces the risk of developing back pain after surgery. Spinal anesthesia is commonly used but may cause discomfort or persistent back pain in some patients. By comparing standard techniques, ultrasound guidance, and sedation, we aim to find safer and more comfortable approaches for patients undergoing non-obstetric surgery.",[176,177,26],"Pain Management","Postoperative Acute Pain",[179,180,181,182,183],"Spinal anesthesia","Ultrasound-guided anesthesia","Pre-procedure sedation","Midazolam","Chronic back pain","2025-11-14",{"date":186,"type":36},"2025-11-17",{"date":188,"type":36},"2025-10-01",{"date":190,"type":20},"2026-05-10",{"name":192,"class":43},"Benha University",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":163},"100456177","motivate-to-improve-outcomes-for-older-veterans-with-musculoskeletal-pain-and-depression-100456177","NCT05220202","MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression","MOTIVATE_IIR","Inclusion Criteria:\n\n* Aged 60 and older\n* English- speaking\n* Self-reported MSK pain (include cLBP +\u002F- radiating symptoms, OA, fibromyalgia) on most days for the past 3 months that interferes with daily activities\n* Pain intensity that is 4+\u002F10 on the numerical pain rating scale\n* Pain interference threshold 5+ on PEG-3\n* Depressive symptoms, 10+ on PHQ-9\n* Capable of participating in home-based activity\n* Interested in participating in a non-pharmacologic program\n\nExclusion Criteria:\n\n* Aged 59 or less\n* No telephone\n* Not English speaking\n* Unwilling to be randomized to either study arm\n* Not interested in participating in a non-pharmacologic program\n* Self-reported uncorrected hearing and visual impairments precluding ability to participate in telephone sessions or read pedometer screen\n* Significant (moderate or severe) cognitive impairment (3+ errors) on six-item screening exam\n* Self-reported dependence on wheelchair, bed-bound, or severe balance impairment or severe OA\\* (resulting in inability to participate in physical activity intervention)\n* Illness requiring hospitalization within the last 3 months that interferes with a home-based physical activity intervention (e.g., fall, gout attack, stroke, heart attack, heart failure, surgery for blocked arteries)\n* Suicidal intent (see suicide screening protocol), uncontrolled psychotic disorder or psychiatric hospitalization within 1 year, or enrolled in active substance use program (confirmed with scripted protocol over telephone)","60 Years","99 Years",{"count":203,"type":20},264,[23],"The proposed study seeks to evaluate effectiveness, implementation processes, and cost of MOTIVATE among older Veterans with chronic musculoskeletal (MSK) pain and comorbid depressive symptoms.",[26,153,207,135],"Aging",[26,153,209,207,135],"Veterans","2025-08-15",{"date":212,"type":36},"2025-08-20",{"date":214,"type":36},"2023-09-20",{"date":216,"type":20},"2026-12-01",{"name":218,"class":219},"VA Office of Research and Development","FED",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":4,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":247,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":251,"locationsCount":4},"100603518","celz-201-ddt-for-the-treatment-of-chronic-lower-back-pain-100603518","NCT07137559","CELZ-201-DDT for the Treatment of Chronic Lower Back Pain","Expanded Access Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain","ADAPT","Inclusion Criteria:\n\n* Confirmed diagnosis of chronic lower back pain due to degenerative disc disease.\n* No comparable or satisfactory alternative therapy available. Unable to participate in the ongoing CELZ-201-DDT clinical trial. Informed consent provided.\n\nExclusion Criteria:\n\n* Any medical condition that poses an unacceptable risk or would interfere with treatment safety or evaluation.\n* Known hypersensitivity to any component of the investigational product.\n\nHow to Request Access:\n\n* Contact the Expanded Access Coordinator to confirm eligibility and discuss feasibility.\n* Complete and submit FDA Form 3926 to the appropriate FDA review division.\n* Obtain IRB review (may be expedited or post-treatment for emergency use). Coordinate drug shipment and treatment schedule.","80 Years","EXPANDED_ACCESS","CELZ-201-DDT is an investigational (experimental) cell therapy currently being studied for people with degenerative disc disease who have chronic lower back pain.",[26,232],"Degenerative Disc Disease Lumbar",[234,235,236,237,238,239,105,240,241,242,243,244,245,246],"CELZ-201-DDT","Allogeneic Umbilical Cord Sub-Epithelial Cell-Derived Mesenchymal Stromal Cells","Mesenchymal Stromal Cells (MSC)","Chronic Lower Back Pain","Degenerative Disc Disease (DDD)","Lumbar Degeneration","Expanded Access","Single Patient IND","Emergency Use IND","Non-Emergency Use IND","Compassionate Use","Regenerative Medicine","Stem Cell Therapy","AVAILABLE","2025-08-14",{"date":250,"type":36},"2025-08-22",{"name":252,"class":120},"Creative Medical Technology Holdings Inc",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":65},"100565355","healing-track-clinical-trial-100565355","NCT06641102","Healing Track Clinical Trial","Healing Track Randomized Clinical Trial","Inclusion Criteria:\n\n* Aged 21 to 70\n* Chronic Back Pain- CBP will be defined according to the criteria established by a recent NIH task force\n* Pain duration must be at least 3 months, with back pain being an ongoing problem for at least half the days of the last 6 months. That is, patients can meet criteria by either reporting pain every day for the past 3 months, or by reporting pain on half or more of the days for the past 6+ months.\n* Patients must rate pain intensity at 4\u002F10 or greater on the Brief Pain Inventory-Short Form (BPISF) (on the item measuring average pain over the last week).\n* Participants must also be comfortable and able to communicate via email or text message, as several study measures are collected in this manner.\n* Able to use a smartphone\n\nExclusion Criteria:\n\n* Back pain associated with compensation or litigation issues as determined by self-report within the past year\n* Leg pain is greater than back pain, as this suggests neuropathic pain, which may be less responsive to psychotherapy\n* Cauda Equina syndrome, as screened for by self-reported inability to control bowel or bladder function\n* Self-reported diagnoses of schizophrenia, multiple personality disorder, or dissociative identity disorder\n* Self-reported use of intravenous drugs, due to concerns about infections and subject compliance with experimental protocols","21 Years","70 Years",{"count":172,"type":20},[23],"This is a randomized clinical trial to evaluate a digital pain reprocessing therapy (PRT) intervention for chronic back pain (CBP).\n\nThe purpose of this research is to test whether a new digital treatment for chronic pain works as well as traditional treatments for chronic back pain (CBP). Some people with CBP experienced side effects from other treatments, or previous treatments did not relieve pain, so this research aims to see if a digital therapy is a better option for CBP.\n\nThis study will assess changes in pain intensity from PRT intervention compared to a standard of care (SOC) control group in adults with CBP. SOC is defined as a comprehensive clinical care plan, including a consultation with physiatrist and prescribed interventions, which will capture a comparison representative of all potential interventions that are recommended for an individual.\n\nThe research team plans to enroll 180 participants who will be randomized into one of three groups.",[26],"2025-07-15",{"date":268,"type":36},"2025-07-18",{"date":270,"type":36},"2025-05-12",{"date":272,"type":20},"2026-03-01",{"name":274,"class":43},"Icahn School of Medicine at Mount Sinai",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":281,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":284,"phases":4,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":65},"100538242","behavioral-and-cognitive-predictors-of-persistent-pain-and-opioid-misuse-in-chronic-pain-100538242","NCT06288282","Behavioral and Cognitive Predictors of Persistent Pain and Opioid Misuse in Chronic Pain","Inclusion Criteria:\n\n* With diagnoses related to chronic lower back pain\n* Age above 18yrs\n* Non pregnant\n\nExclusion Criteria:\n\n* Cancer pain",true,{"count":283,"type":20},130,"OBSERVATIONAL","Chronic lower back pain (CLBP) affects approximately 20% of the global population. The study objective is to determine if impulsivity, inhibitory control, drug choice, and\u002For cognitive distortions predict opioid misuse and disability in patients with chronic pain. This is a prospective consented cross-sectional study characterizing behavioral and cognitive phenotypes using both patient-reported survey measures and cognitive testing. Outcome measures include correlations between impulsivity measures, opioid drug choice responses and cognitive distortion scores, and risk for opioid misuse (Primary outcomes: COMM scores, SOAPPR scores). Secondary outcomes is BPI measurement. A Certificate of Confidentiality will provide additional protections for participants.",[26],"2025-06-09",{"date":289,"type":36},"2025-06-12",{"date":291,"type":36},"2023-12-20",{"date":293,"type":20},"2025-12",{"name":274,"class":43},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":260,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":65},"100585733","low-intensity-focused-ultrasound-for-chronic-pain-high-resolution-targeting-of-the-human-insula-100585733","NCT06906211","Low Intensity Focused Ultrasound for Chronic Pain: High Resolution Targeting of The Human Insula","LIFU_Pain","Inclusion Criteria:\n\n* Veterans aged 21 to 75 with Chronic Back Pain (CBP).\n* CBP duration daily for last 3 months or half of days for last 6 months\n* Endorse pain rating of 4\u002F10 BPI-SF\n* Evidence of widespread pain symptoms as determined by report of CBP and pain in a contralateral limb (pain in the upper, lower, left or right side of the body) in fewer than 11 sites. Upper body sites include hand, wrist, elbow or shoulder. Lower sites include hip, knee, ankle or foot.\n\nExclusion Criteria:\n\n* Surgery recommended as primary treatment intervention for CBP\n* Current diagnosis of fibromyalgia\n* Current substance use disorder other than nicotine.\n* Psychiatric disorder and not on a stable pharmacologic regimen for ≥ 4 weeks prior to screening\n* Opiate use daily\n* Currently pregnant or breast feeding.\n* Unable to understand the consent form.\n* History of head injury with loss of consciousness for more than 5 minutes, seizures, history of stroke, brain surgery, brain tumor, multiple sclerosis.\n* History of metastatic cancer, rheumatoid arthritis, polymyalgia rheumatica, scleroderma, lupus, or polymyositis\n* Unintended weight loss of 20 pounds or more in the last year\n* Cauda equina syndrome\n* Ferromagnetic implants or other contraindications for MRI\n* Uncompensated congestive heart failure, unstable angina, poorly controlled arrhythmia, active systemic infection end stage renal disease.","75 Years",{"count":304,"type":20},66,[23],"In this study, the research team will use low-intensity focused ultrasound (LIFU) to temporarily change brain activity in a brain region that is known to be involved in chronic pain. Through this, the research team hopes to learn about how the brain area works in response to pain. There are main questions this study aims to answer:\n\n* The effect of LIFU to inhibit the posterior region of the insula (PI) compared to sham stimulation in individuals with chronic back pain (CBP) and widespread pain symptoms.\n* The effect of LIFU to PI compared to sham stimulation to reduce pain intensity and magnitude of the Neurologic Pain Signature (NPS) in response to evoked thermal pain.\n* The effect of LIFU to PI compared to sham stimulation to reduce pain intensity and magnitude of Tonic Pain Signature in response to tonic pain.",[26,308],"Chronic Pain (Back \u002F Neck)",[310,29,311,312],"low intensity focused ultrasound","chronic pain","functional magnetic resonance imaging","2025-03-25",{"date":315,"type":36},"2025-04-02",{"date":317,"type":36},"2025-01-15",{"date":319,"type":20},"2028-01-26",{"name":321,"class":219},"Washington D.C. Veterans Affairs Medical Center",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":281,"sex":16,"minAge":17,"maxAge":302,"enrollmentInfo":330,"targetDuration":4,"studyType":21,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":65},"100550902","focused-ultrasound-for-the-complex-patient-100550902","NCT06453109","Focused Ultrasound for the Complex Patient","Towards Treatment of the Complex Patient: Investigations of Low-intensity Focused Ultrasound","LIFU","Inclusion Criteria:\n\n1. Males and females aged 18-75 years\n2. Current diagnosis of Chronic Back Pain as defined by pain duration of at least three months, with back pain being an ongoing problem for at least half the days of the last six months.\n3. Have evidence of central sensitization (CS) as measured by the Widespread Pain\u002FSymptom Severity Index (WPSSI) with a score of Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) ≥ 5 or WPI = 3-6 and SS ≥ 9.\n4. Participants must rate pain intensity at 4\u002F10 or greater on the Brief Pain Inventory-Short Form (BPI-SF)\n5. Meet the DSM-5 criteria for current opiate use disorder as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.\n6. Be in treatment for OUD including buprenorphine or methadone.\n7. Meet the DSM-5 criteria for a current anxiety disorder: generalized anxiety disorder, post-traumatic stress disorder or social anxiety disorder as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM-5).\n\nExclusion Criteria:\n\n1. Evidence of neuropathic pain\n2. Current DSM-5 substance use disorder other than OUD, tobacco use disorder\n3. Current DSM-5 diagnosis of schizophrenia or schizo-affective disorder\n4. Pregnant or breastfeeding\n5. Daily use of benzodiazepines or opiates (other than buprenorphine or methadone)\n6. History of seizures, neurologic disorders, including cerebrovascular disease, history of stroke, brain surgery, brain tumor, multiple sclerosis, or neurodegenerative diseases. They will not have history of metastasizing cancers, inflammatory disorder: rheumatoid arthritis, polymyalgia rheumatica, scleroderma, lupus or polymyositis, unintended weight loss of 20 pounds or more in the last year, or cauda equina syndrome.\n7. Ferromagnetic implants or other contraindications for MRI\n8. Unstable medical conditions such as congestive heart failure, unstable angina, poorly controlled arrhythmia active systemic infection end stage renal disease.",{"count":331,"type":20},25,[23],"The goal of this clinical trial is to to inhibit the anterior insula (AI) with low intensity focused ultrasound (LIFU) to determine the causal role for the AI in pain processing, anxiety, and opiate cue-induced craving. The main question\\[s\\] it aims to answer are:\n\n* the safety and tolerability of LIFU delivered bilaterally to AI compared to sham stimulation in individuals with opiate use disorder (OUD), anxiety, and chronic back pain\n* the effects of LIFU vs sham on measures of pain processing, anxiety symptoms, and opiate cue-induced craving\n\nParticipants will undergo anatomical MRI, neurological assessment, clinical assessment and patient query to assess the safety and tolerability of LIFU vs sham.",[335,26,152],"Opioid Use Disorder",[337,338,339,340,109,29,341,342,343,310,344],"anxiety disorders","oud","opiate use disorder","opioid","opioid use","opioid abuse","opioid disorder","transcranial ultrasound","2024-11-15",{"date":347,"type":36},"2024-11-20",{"date":349,"type":36},"2024-04-29",{"date":351,"type":20},"2025-09-30",{"name":321,"class":219}]